Md Selim Reza

Dr. Md Selim Reza


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 October 2025 in Applied Sciences
Verified
Journal Article
Open access
PDF file
MAMd Imtyaz Ahmed
Md Imtyaz Ahmed
DHDelwar Hossain
Delwar Hossain
MRMd Mostafizer Rahman
Md Mostafizer Rahman
MMMd. Shahajada Mia
Md. Shahajada Mia
Yutaka WatanobeYutaka Watanobe
Yutaka Watanobe
MAMd Ashad Alam
Md Ashad Alam
Cancer exhibits diverse and complex phenotypes driven by multifaceted molecular interactions. Recent biomedical research has emphasized the comprehensive study of such diseases by integrating multi-omics datasets (genome, proteome, transcriptome, epigenome). This approach provides an efficient method for identifying genetic variants associated with cancer and offers a deeper understanding of how the disease develops and spreads. However, it is challenging to comprehend complex interactions among the features of multi-omics datasets compared to single omics. This study investigates multi-omics lung cancer data obtained from The Cancer Genome Atlas (TCGA) repository. Differentially expressed genes were identified using four statistical approaches: LIMMA, T-test, Canonical Correlation Analysis (CCA), and the Wilcoxon test applied across gene expression (GE), DNA methylation, and microRNA (miRNA) datasets. Kernel Machine Regression (KMR) was subsequently employed to perform data fusion across the multi-modal datasets. The empirical results highlight notable interactions among GE, miRNA expression, and DNA methylation in lung cancer. Our analysis identified 38 genes that show significant associations with lung cancer. Among these, 8 genes of highest ranking (PDGFRB, PDGFRA, SNAI1, ID1, FGF11, TNXB, ITGB1, and ZIC1) were highlighted by rigorous statistical analysis. Furthermore, in silico studies identified three top-ranked potential candidate drugs (Selinexor, Orapred, and Capmatinib) that may offer promising therapeutic potential against lung cancer. The effectiveness of these candidate drugs is further reinforced by evidence from independent research studies, which emphasize their potential in lung cancer treatment.

17 October 2025 in arXiv
Verified
Preprint
Open access
PDF file
MAMd Imtyaz Ahmed
Md Imtyaz Ahmed
DHDelwar Hossain
Delwar Hossain
MRMd Mostafizer Rahman
Md Mostafizer Rahman
AHAhsan Habib
Ahsan Habib
MRMd. Mamunur Rashid
Md. Mamunur Rashid
MAMd Ashad Alam
Md Ashad Alam
Cancer exhibits diverse and complex phenotypes driven by multifaceted molecular interactions. Recent biomedical research has emphasized the comprehensive study of such diseases by integrating multi-omics datasets (genome, proteome, transcriptome, epigenome). This approach provides an efficient method for identifying genetic variants associated with cancer and offers a deeper understanding of how the disease develops and spreads. However, it is challenging to comprehend complex interactions among the features of multi-omics datasets compared to single omics. In this paper, we analyze lung cancer multi-omics datasets from The Cancer Genome Atlas (TCGA). Using four statistical methods, LIMMA, the T test, Canonical Correlation Analysis (CCA), and the Wilcoxon test, we identified differentially expressed genes across gene expression, DNA methylation, and miRNA expression data. We then integrated these multi-omics data using the Kernel Machine Regression (KMR) approach. Our findings reveal significant interactions among the three omics: gene expression, miRNA expression, and DNA methylation in lung cancer. From our data analysis, we identified 38 genes significantly associated with lung cancer. From our data analysis, we identified 38 genes significantly associated with lung cancer. Among these, eight genes of highest ranking (PDGFRB, PDGFRA, SNAI1, ID1, FGF11, TNXB, ITGB1, ZIC1) were highlighted by rigorous statistical analysis. Furthermore, in silico studies identified three top-ranked potential candidate drugs (Selinexor, Orapred, and Capmatinib) that could play a crucial role in the treatment of lung cancer. These proposed drugs are also supported by the findings of other independent studies, which underscore their potential efficacy in the fight against lung cancer.

13 December 2024
Verified
Book Chapter
Closed access
PDF file
AAAmanat Ullah Arman
Amanat Ullah Arman
MAMuhammad Habibulla Alamin
Muhammad Habibulla Alamin
MRMd Selim Reza
Md Selim Reza
TMTasnia Akter Maya
Tasnia Akter Maya
THTofazzal Hossain
Tofazzal Hossain

1 January 2025 in International Journal of Genomics
Verified
Journal Article
Open access
AAAmanat Ullah Arman
Amanat Ullah Arman
MRMd Selim Reza
Md Selim Reza
MAMuhammad Habibulla Alamin
Muhammad Habibulla Alamin
TMTasnia Akter Maya
Tasnia Akter Maya
MHMd. Tofazzal Hossain
Md. Tofazzal Hossain
Prostate cancer (PCa) is a major malignancy affecting men and is a significant contributor to global male mortality. Over the past decade, several new treatments for advanced PCa have been approved; however, opportunities remain for the development of novel therapeutic strategies. Therefore, in this study, we developed an integrated bioinformatics pipeline to identify potential therapeutic targets and repurposed drugs using RNA‐seq datasets, aiming to advance treatment options for PCa. Using the LIMMA approach, 458 common differentially expressed genes (cDEGs) were analyzed from three publicly available microarray datasets, leading to the identification of 15 hub genes (HubGs) through a protein–protein interaction (PPI) network. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses revealed their critical roles in PCa, and lower expressions of five HubGs (BIRC5, CDCA5, CENPF, NUSAP1, and TK1) correlated with better survival. All of these genes could potentially serve as biomarkers for the detection and therapy of PCa. Following that, we considered these possible genes as targets for drugs, performed docking analysis with 255 meta‐drug agents, and identified the top 10 candidate drugs (adapalene, ergotamine, imatinib, dutasteride, vistusertib, risperidone, zafirlukast, irinotecan hydrochloride, drospirenone, and telmisartan). Finally, we evaluated the binding stability of the top‐ranked three complexes—BIRC5–adapalene, BIRC5–imatinib, and TK1–ergotamine—through a 100 nanoseconds (ns) molecular dynamics (MD) simulation conducted using NAMD. The analysis revealed consistent stability across all complexes. This study uniquely combines multidataset transcriptomic integration, HubG prioritization, and MD validation to propose novel biomarker–drug pairings for PCa. The findings offer promising leads for future experimental and clinical validation.

22 October 2025 in arXiv
Verified
Preprint
Open access
PDF file
MRMd Selim Reza
Md Selim Reza
SASabrin Afroz
Sabrin Afroz
MRMd Mostafizer Rahman
Md Mostafizer Rahman
MAMd Ashad Alam
Md Ashad Alam
Multi-omics data integration is crucial for understanding complex diseases, yet limited sample sizes, noise, and heterogeneity often reduce predictive power. To address these challenges, we introduce Omics-GAN, a Generative Adversarial Network (GAN)-based framework designed to generate high-quality synthetic multi-omics profiles while preserving biological relationships. We evaluated Omics-GAN on three omics types (mRNA, miRNA, and DNA methylation) using the ROSMAP cohort for Alzheimer's disease (AD) and TCGA datasets for colon and liver cancer. A support vector machine (SVM) classifier with repeated 5-fold cross-validation demonstrated that synthetic datasets consistently improved prediction accuracy compared to original omics profiles. The AUC of SVM for mRNA improved from 0.72 to 0.74 in AD, and from 0.68 to 0.72 in liver cancer. Synthetic miRNA enhanced classification in colon cancer from 0.59 to 0.69, while synthetic methylation data improved performance in liver cancer from 0.64 to 0.71. Boxplot analyses confirmed that synthetic data preserved statistical distributions while reducing noise and outliers. Feature selection identified significant genes overlapping with original datasets and revealed additional candidates validated by GO and KEGG enrichment analyses. Finally, molecular docking highlighted potential drug repurposing candidates, including Nilotinib for AD, Atovaquone for liver cancer, and Tecovirimat for colon cancer. Omics-GAN enhances disease prediction, preserves biological fidelity, and accelerates biomarker and drug discovery, offering a scalable strategy for precision medicine applications.

8 April 2026 in Diabetology
Verified
Journal Article
Open access
PDF file
Shah Tanzen JahanShah Tanzen Jahan
Shah Tanzen Jahan
DKDurga H. Kutal
Durga H. Kutal
AAAnicha Akter
Anicha Akter
MRMd Selim Reza
Md Selim Reza
KIKabirul Islam
Kabirul Islam
MHMd Monimul Huq
Md Monimul Huq
Background: Diabetic foot ulcer (DFU) is a major complication of type 2 diabetes (T2D), frequently resulting in disability, lower-limb amputation, and substantial healthcare burden. Early identification of patients at high risk of progressing to severe DFU is essential for timely intervention, yet evidence on associated risk factors remains limited in Bangladesh. This study aims to identify demographic, clinical, and behavioral predictors of severe DFU to support early management strategies. Methods: A cross-sectional study was conducted among 159 DFU patients attending the Rajshahi Diabetic Association General Hospital, Bangladesh. Data on demographic characteristics, clinical variables, and behavioral factors were obtained through structured questionnaires and standardized examinations. Severe DFU was defined as Wagner grades 3–5, while grades 0–2 were considered non-severe. Firth’s penalized logistic regression was used to identify determinants of severe DFU. Model performance was assessed using ROC analysis, calibration belt analysis, and decision curve analysis (DCA). Results: Among the 159 participants, 101 (63.5%) presented with severe DFU. Patients with severe DFU had significantly higher BMI (26.1 vs. 23.7 kg/m2), treatment costs (50,000 vs. 20,000 BDT), and were older (57 vs. 54 years). Severe DFU was also associated with higher prevalence of peripheral arterial disease (PAD) (29.7% vs. 3.4%), prior amputation (31.7% vs. 3.4%), peripheral neuropathy (PN) (86.1% vs. 58.6%), and poor glycemic control (71.3% vs. 30.7%) (all p < 0.05). Firth’s regression identified older age (aOR 1.08), poor glycemic control (aOR 3.90), PN (aOR 3.41), PAD (aOR 7.54), and previous amputation (aOR 13.67) as independent predictors of severe DFU. Conclusions: Older age, uncontrolled glycemia, PN, PAD, and prior amputation were significantly associated with severe stages of DFU. Early detection and targeted management of these factors are critical to reducing complications and lowering the healthcare burden.